Disease: Melanoma  
Treatment: Immunotherapy  
AssayName: high-resolution mass spectrometry  
GeneticModification: CRISPR-Cas9 knockouts  
MaterialType: clinical samples  
MaterialType: archival formalin-fixed paraffin-embedded (FFPE) tissues  
Disease: metastatic melanoma  
Treatment: TIL-based adoptive cell transfer  
Experiment: “Young TIL” protocol  
Experiment: “Selected TIL” protocol  
Organism: mouse  
CellLine: WM266–4  
CellLine: WM115  
CellLine: A375  
CellLine: Mel526  
CellLine: Mel624  
CellLine: YUMMER1.7 (clone D4J)  
Compound: Sodium dichloroacetate (DCA)  
ConcentrationOfCompound: 30 mM  
Compound: avasimibe  
ConcentrationOfCompound: 3 μM  
Compound: etomoxir  
ConcentrationOfCompound: 100 μM  
Compound: rotenone  
ConcentrationOfCompound: 200 nM  
Compound: antimycin  
ConcentrationOfCompound: 250 nM  
Compound: oligomycin  
ConcentrationOfCompound: 50 nM  
Compound: DMSO  
SampleTreatment: DMSO treatment  
Compound: sodium dodecyl sulfate (SDS)  
Compound: Tris pH 7.6  
ReductionReagent: DTT  
AlkylationReagent: iodoacetamide  
CleavageAgent: trypsin  
Compound: trifluoroacetic acid  
ConcentrationOfCompound: 1%  
FractionationMethod: strong anion exchange (SAX) chromatography  
Compound: 2–2-2 trifluoroethanol (TFE)  
Compound: ABC  
ConcentrationOfCompound: 25 mM  
CleavageAgent: Lys-C-Trypsin mix  
FractionationMethod: strong cation exchange (SCX) chromatography  
Instrument: Q-Exactive Plus  
Instrument: Q-Exactive HF mass spectrometers  
Separation: 50 cm EASY-spray PepMap column  
GradientTime: 220 min  
GradientTime: 140 min  
FlowRateChromatogram: 300 nL/min  
Temperature: 40°C  
Compound: formic acid  
ConcentrationOfCompound: 0.1%  
Compound: acetonitrile  
ConcentrationOfCompound: 80%  
FractionIdentifier: 3.5 μm  
Instrument: Gallios flow cytometer  
Instrument: BD LSRII flow cytometer  
FactorValue: 10:1 Effector:Target ratio  
Treatment: tumor infiltrating lymphocyte (TIL)-based immunotherapy  
Treatment: anti- programmed death 1 (PD1) immunotherapy